All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1900+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

AstraZeneca and Daiichi Sankyo's Enhertu (targeting HER2) lands in EC approval in for HR-positive, HER2-low/ultralow metastatic breast cancer
Antibody-drug conjugate (ADC), breast cancer - Read more

AstraZeneca's Imfinzi (targeting PD-L1) with chemotherapy lands EC approval for resectable non-small cell lung cancer without EGFR mutations or ALK rearrangements
Monoclonal antibody, lung cancer - Read more

PRESENTED BY TLDR BIOTECH
What would you do with 7k+ meticulously tagged biotech & pharma data points?
Free gene-editing data set below!

Over the past year, TLDR Biotech has been collecting and categorizing industry news across approvals, clinical trials, fundraises, partnerships, M&A, politics & policy, and much much more.

Each data point is tagged by drug modality, disease indication, tech area, and even more specific categories. For example:

🔍 Need to track all small molecule fundraises across oncology?

📈 Want a curated list of recent cell therapy clinical trials updates (both the successes and failures)?

💡 Looking for trends in Alzheimer's and Parkinson's disease partnerships?

Here’s a free set of data - gene-editing stories over the last 4 months.

We’re leveraging this resource to build tailored reports and curated insights for select clients—and now you can get full access.

Ready to get access or have questions? Check out our landing page.

✅ More Good News ✅

THE GOOD
Clinical Trials

Arvinas' ARV-102 (targeting LRRK2) delivers positive Ph1 trial results in Parkinson’s disease
Small molecule, Parkinson's disease - Read more

Sarepta Therapeutics's Elevidys clinical trials lands continuation recommendation from data monitoring committee, days after EMA recommends clinical hold after US patient death
Gene therapy, Duchenne muscular dystrophy (DMD), adeno-associated virus (AAV) - Read more

Johnson & Johnson's Tremfya (IL-23 inhibitor) delivers positive Ph3b data in active psoriatic arthritis
Monoclonal antibody, psoriatic arthritis - Read more

Beam Therapeutics touts additional positive Ph1/2 data for BEAM-302, base editing treatment for alpha-1 antitrypsin deficiency
Gene-editing, base-editing, alpha-1 antitrypsin deficiency - Read more

RiboX Therapeutics begins world first first human trial of circular RNA therapy, a genetic medicine for chronic diseases between mRNA and gene therapies
RNA, circular RNA, radiation-induced-xerostomia, hyposalivation - Read more

THE GOOD
Fundraises

RayThera $110M Series A, advancing small molecule immunology drug candidates through Phase 1 clinical studies
Small molecule, Immunology, Inflammatory disease - Read more

Sanofi and Cathay Capital launch $275.1M innovation fund targeting clinical-stage drug pipeline in China
Biotech Investing, asset-focused fund - Read more

Aptevo Therapeutics $2.1M registered direct offering, developing immune-oncology therapeutics with ADAPTIR platforms for cancer treatment
Bispecific antibody, cancer, myeloid leukemia, platform technology - Read more

Ernexa Therapeutics $7.25M private placement, developing iPSC-derived cell therapies for cancer and autoimmune diseases
Cell therapy, cancer, autoimmune disease, induced pluripotent stem cell (IPSC/iPS cell), stem cell-derived therapy - Read more

restor3d $38M growth capital, creating personalized 3D printed orthopedic implants and launching new product lines
Medical device, orthopedic implants - Read more

Tasman Therapeutics planning for a $175M Series A, developing oral ketamine tablet for Treatment-Resistant Depression
Small molecule, psychedelics, treatment-resistant depression, planned fundraise - Read more

THE GOOD
IPOs

Vickers Venture Partners filed for $180M IPO for second SPAC, seeking acquisition after first merged with Scilex
SPAC, biotech investing - Read more

THE GOOD
Lawsuits

GSK and Pfizer settle RSV patent lawsuit amid market challenges and UK court ruling against GSK
Respiratory syncytial virus (RSV), vaccine, patent suit - Read more

THE GOOD
Mergers & Acquisitions

F-star Therapeutics splits from invoX Pharma to become independent company after 2023 acquisition, continuing focus on bispecific antibodies
Bispecific antibody, cancer, platform technology, drug discovery - Read more

London biotech Epsilogen acquires TigaTx, combining IgE antibodies and neutrophil engager technology for cancer treatment advancements
Antibody, cancer, solid tumor - Read more

Sartorius acquiring MatTek's 3D microtissue business from BICO for $80 million, expected to close in Q2 2025
Microtissue models, tissue models - Read more

THE GOOD
Partnerships

Kyowa Kirin, La Jolla Institute for Immunology renew 35-year research partnership advancing immunology discoveries and rare disease therapies
Drug discovery, antibody, cell therapy, gene therapy - Read more

THE GOOD
Politics & Policy

Mehmet Oz confirmed as CMS administrator; will oversee healthcare programs amid job cuts and potential Medicaid changes
Centers for Medicare and Medicaid Services (CMS) - Read more

THE GOOD
Product Launches

ResMed launches NightOwl, a fingertip sensor for home sleep apnea testing, now available nationwide to improve diagnosis rates
At-home testing, sleep apnea - Read more

THE GOOD
Public Health

RJK Jr. states MMR vaccine is most effective against measles, despite past concerns
Vaccine, measles - Read more [Paywall]

THE GOOD
Research

MIT engineers develop system to mass-produce nanoparticles that deliver cancer drugs directly to tumors, advancing potential clinical use
Drug delivery, nanoparticle, cancer - Read more

THE GOOD
Strategic Plans

AGC Biologics launches Cell and Gene Technologies Division, appointing Luca Alberici to lead global operations from Milan
Cell therapy, gene therapy, cell therapy manufacturing, gene therapy manufacturing, CDMO (Contract Development & Manufacturing Organization), viral vector manufacturing, Research & Development - Read more

PRESENTED BY YOU?
Get the attention of 1900+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Company Shutdown

DyNAbind, building DNA-Encoded Libraries for drug discovery, shuts down after nearly eight years in operation
DNA-encoded library, drug discovery - Read more

THE BAD
Layoffs

Relay Therapeutics cuts 70 jobs in third layoff within a year, reducing annual research budget by 75% to extend cash runway
Small molecule, breast cancer, AI - Read more

Spark Therapeutics cuts 298 Philadelphia jobs in reorganization, integrating 310 employees into parent company Roche
Gene therapy, hemophilia, Leber's congenital amaurosis, retinitis pigmentosa - Read more

THE BAD
Partnerships

Apollomics, TYG Oncology, termination of immuno-oncology partnership for TYG100/APL-810 cancer vaccine amid cost-cutting measures
Cancer vaccine, cancer - Read more

THE BAD
Patient Access

Trump administration rejects Biden's proposed rule to expand Medicare coverage for weight loss drugs like Wegovy and Zepbound
GLP-1, obesity, drug access, health insurance, Centers for Medicare and Medicaid Services (CMS) - Read more

THE BAD
Politics & Policy

Lilly CEO Ricks warns drug tariffs would reduce R&D spending, despite pharma's temporary exemption from Trump's recent tariffs
Research & Development, tariffs, big pharma strategy - Read more

THE UGLY
Lawsuits

16 state attorneys general sue Trump administration over NIH research grant terminations, challenging funding cuts as unlawful
National Institute of Health (NIH), federal research funding - Read more

THE UGLY
Politics & Policy

China's 34% retaliatory tariffs on US imports could further challenge drugmakers facing weakened demand and competition in China
Tariffs - Read more [Paywall]

CDC division for environmental health cut, eliminating asthma, lead poisoning, and radiation emergency response resources.
Centers for Disease Control and Prevention (CDC), lead poisoning, asthma - Read more [Paywall]

RFK Jr. admits 20% of 10,000 HHS layoffs were mistakes, plans to some rehire affected staff multiple departments
Public agency layoffs, US Department of Health & Human Services (HHS) - Read more

THE UGLY
Regulatory

FDA staff cuts threaten drug review processes, as RFK Jr.'s purge impacts essential personnel despite sparing direct reviewers
Drug approval process, Food & Drug Administration (FDA), Public agency layoffs - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here